Pharmacokinetics of recombinant transgenic antithrombin in volunteers

Anesthesia and Analgesia

Volumn 90, Issue 3, 2000, Pages 531-534

  Lu, Wei ^a   Mant, T G K ^b   Levy, Jerrold H ^a   Bailey, James M ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GUY S HOSPITAL   (United Kingdom)

^c EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III; HEPARIN;

ANTICOAGULATION; ARTICLE; CARDIOPULMONARY BYPASS; DISTRIBUTION VOLUME; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0034092626     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-200003000-00006     Document Type: Article

References (16)

1. Bucur SZ, Levy JH, Despotis GJ, et al. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion 1998;38:481-98.
2. Choay J, Petitou M, Lormeau JC, et al. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high antifactor Xa activity. Biochem Biophys Res Commun 1983;116:492-9.
3. Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:258S-75S.
4. Despotis GJ, Levine V, Joist JH, et al. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg 1997;85:498-506.
5. Hashimoto K, Yamagishi M, Sasaki T, et al. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1995;58: 799-805.
6. Esposito RA, Culliford AT, Colvin SB, et al. Heparin resistance during cardiopulmonary bypass: the role of heparin pretreatment. J Thorac Cardiovasc Surg 1983;85:346-53.
7. Zaidan JR, Johnson S, Brynes R, et al. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery. Anesth Analg 1986;65: 377-80.
8. Fitch JCK, Smith MJ, Rinder CS, Smith BR. Supplemental antithrombin preserves platelet count and decreases platelet activation during in vitro bypass [abstract]. Anesth Analg 1996;82: SCA3.
9. Sheiner LB, Rosenberg B, Marathe W. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977;5:445-479.
10. Boeckmann A, Sheiner LB, Beal SL. NONMEM user' guide. San Francisco: NONMEM Project Group, 1992.
11. Schwartz RS, Bauer KA, Rosenberg RD, et al. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin: The Antithrombin III Study Group. Am J Med 1989;87:53S-60S.
12. Irani MS. Antithrombin concentrates in heparin-resistant cardiopulmonary bypass patients. Clin Appl Thromb Hemostas 1996;2:103-6.
13. Montes FR, Levy JH. Can we alter heparin dose-responses with antithrombin III? [abstract]. Anesth Analg 1996;82:SCA94.
14. Boisclair MD, Lane DA, Philippou H, et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993;82:3350-7.
15. Slaughter TF, LeBleu TH, Douglas JM Jr, et al. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994;80:520-6.
16. Despotis GJ, Joist JH, Hogue CW, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996;76:902-8.